Genomictree (228760) 🔎 In-depth
KOSDAQ · Price as of 2026-08-06 · Updated 2026-08-09
Genomictree is a molecular-diagnostics company that finds cancer early by using 'DNA methylation,' a chemical tag attached to genes, as a clue, with the center of its revenue being EarlyTect, which screens for colorectal cancer from stool, and test kits and services that check for bladder cancer from urine. With 2025 revenue of ₩3.8 billion (+59.2%) the scale is still small, but revenue is growing at rates from the double digits to around 50%, the operating loss has narrowed for three straight years, Q1 (+20.6%) confirmed revenue growth alongside a continuing loss, and its price against assets (P/B of 2.33x) is lower than peers. The key point of late is that it is strong when test revenue steadily rises, the loss narrows, and overseas approvals such as entry into the U.S. colorectal-cancer screening market advance, whereas if revenue stalls again or the loss drags on, the timing of the swing to profit remains a large variable in judging value.
This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.
30-second brief
Pulled directly from the computed values below — not a separately written opinion.
What do the SourceComputedEstimateReading tags mean?
Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.
Core valuation metric
This stock's effective sub-sector is “Diagnostics & Molecular Diagnostics” (Biotech & Pharmaceuticals · Biotech (Drug Development & Research)), a type typically read first through P/E.
Molecular diagnostics firms often earn real profits from testing services and products, so price-to-earnings (P/E) — the price against those profits — is the default starting point. But in a loss-making year, driven by demand swings or heavier investment, earnings-based multiples break down, so you read EV/Sales — enterprise value against revenue — instead.
Price against earnings alone becomes unstable when earnings swing. Reading it together with price against assets helps gauge the downside.
That said, meaningful revenue has yet to ramp, so pipeline value and cash runway may matter more than this metric.
This note explains how each sector is typically valued and is educational context only, not investment advice.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue rose 59.2% year over year, and the pace is quickening (3-year trend: mixed).
- Most recent quarter (Q1 2026) revenue was 20.6% higher than a year earlier.
- ROE is -7.8% (controlling-interest basis). It is above the sector average.
- Operating margin is -300.5%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Ahn Sung-hwan 13.33% (individual)
Controlling bloc incl. related parties 15.77%
With the controlling bloc holding 16%, control is maintained but the free float is relatively large.
🔎 In-depth analysis Reading
Genomictree is a molecular-diagnostics company that finds cancer early by using 'DNA methylation' (a phenomenon in which a chemical tag attaches to a specific gene region and switches off that gene's function) as a clue. It has two flagship products. The first is EarlyTect, a colorectal-cancer early-screening test that detects methylation of a colorectal-cancer-related gene (SDC2) in stool; the second is a test that checks for bladder cancer from urine. Its way of earning money centers on revenue from these test kits and testing services, with technology-out-licensing and R&D-related income added on top. Current revenue scale is still small at about ₩3.8 billion a year, and the core of the company's value depends less on today's profit than on how widely the tests come to be used. In particular, entry into the U.S. colorectal-cancer screening market (with local trials and approvals underway) is the crux of medium- to long-term growth.
The latest close is ₩13,020 and the market capitalization is ₩323.7 billion. The price sits above its 20-day moving average (₩11,713) and above its 60-day moving average (₩12,269). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 58.5, a neutral level. The one-month change is +17.0%, the three-month change is -19.4%, and the position relative to the 52-week high is -59.3%. Relative strength versus the KOSDAQ is 53 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 53% of all stocks. Over the past three months it outpaced the index by 22.4%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Because the confirmed full-year (2025) results were in the red, the P/E (how many times a year's profit the price represents) cannot be computed. Instead, looking at the P/B (how many times net asset value per share the price represents), it is 2.33x, far below the peer median (9.34x) on an asset basis. On this point alone the share price is cheap against asset value, and the official classification diagnosis also views the valuation as undervalued. ROE (the ratio of how much is earned in a year on shareholders' equity) is -7.8% and the operating margin (the share of operating profit in revenue) is -300.5%, still a stage where costs exceed revenue. That said, the debt-to-equity ratio (the ratio of debt to shareholders' equity) is 105.0%, not heavy, and the current ratio (assets soon convertible to cash versus debt due within a year) is 17.8x, so short-term funding is ample. For a loss-making company, rather than taking the P/E and P/B at face value as expensive, it is right to look together at the point where revenue catches up with costs and profit swings into the black. In sum, its financials are those of a diagnostics company on the verge of commercialization, with financial stability that can hold and a share price low against assets.
Revenue dipped once, from ₩3.4 billion in 2023 to ₩2.4 billion in 2024, then turned back up, rising 59.2% from the prior year to ₩3.8 billion in 2025. Q1 2026 revenue also rose 20.6% from the same period a year earlier, so the recovery flow is continuing on a quarterly basis. A point to look at alongside is the size of the loss. The operating loss narrowed each year, from -₩17.3 billion in 2023 to -₩15.3 billion in 2024 and -₩11.3 billion in 2025, so the figures confirm the business gradually catching up with costs as revenue grows. Behind this growth are the expansion of colorectal-cancer early-screening test revenue and entry work into overseas markets such as the United States. That said, the company has not confirmed an official profit outlook for this year, so it is hard to put forward (forward-looking estimated) profit into a number. For this stock, therefore, rather than chasing a fixed forward profit, the key is to directly follow whether test revenue keeps rising each quarter and the loss keeps narrowing.
Recent disclosures center on shareholder returns and results checks. In May 2026 a decision to dispose of treasury shares and a report on its results came out; treasury-share disposal is the process by which a company puts shares it held back onto the market, possibly to secure cash or to make use of the shares, so it is best viewed together with the cash flow. The Q1 2026 quarterly report filed on May 15 shows revenue growth and a continuing loss at the same time. In March there were the 2025 business report (annual revenue ₩3.8 billion, +59.2%) and governance disclosures such as the general shareholders' meeting and appointment of outside directors. For a diagnostics company, business disclosures such as test approvals, technology out-licensing, and supply contracts are large variables for the share price, but this stretch was dominated by periodic and financial disclosures rather than such large business disclosures.
The strengths are clear. Revenue is again rising at rates from the double digits to around 50% (2025 +59.2%, Q1 +20.6%) and the operating loss has narrowed for three straight years, so the direction of test revenue catching up with costs shows in the figures. Debt and short-term liquidity burdens are not heavy either, leaving financial strength to push commercialization forward, and its price against assets (P/B of 2.33x) is lower than peers. There are also points to be careful of. The revenue scale itself is still small and the operating loss continues, so the timing of the swing to profit is a large variable in judging value. On balance, this stock is strong when test revenue steadily rises each quarter, the loss narrows, and overseas approvals advance, and weak when revenue stalls again or the loss drags on. A low P/B is a signal that the share price is cheap against assets, and as a loss-making company this strength becomes clearer when actual revenue and profit trends back it up.
🔎 Valuation vs peers Inconclusive
A domestic molecular-diagnostics and bio peer set close in business substance was chosen. Seegene is a representative PCR-based molecular-diagnostics company whose testing business structure is most similar, and EuBiologics was referenced as a small-cap KOSDAQ bio company similar in revenue scale and growth band. Because the peer sample is small, the base-industry median is viewed only as a supplement.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Seegene | 31.05x | 1.47x | 6.42% |
| EuBiologics | 7.77x | 1.79x | 16.27% |
(a) Position versus true peers: while Seegene and EuBiologics are already profitable so a P/E is available, Genomictree is loss-making and has no P/E, so an over-/under-valuation comparison on the same basis does not hold. (b) Premium/discount: on P/B alone it is 2.72x, higher than the profitable peers, so it is hard to see it as discounted against assets; rather, some growth expectation is already reflected. (c) Limits of trailing (last-year confirmed) and the forward basis: last year's confirmed results were in the red and cannot be converted into a P/E, and the future can only be gauged from a seasonality approximation of DART quarterly results since there is no official company outlook. Being at an inflection stage where profit bends into the black, rather than declaring it cheap or expensive on a single indicator, it is more appropriate to confirm quarter by quarter whether revenue growth and loss narrowing actually continue, so judgment is held.
Earnings outlook Estimate company-stated · verified
| Type | Period | Revenue | Operating profit | Net profit |
|---|---|---|---|---|
| Next quarter | Q2 2026 | approx. ₩0.7 billion | — | — |
Price history Close · MA20 · MA60
The latest close is ₩13,020 and the market capitalization is ₩323.7 billion. The price sits above its 20-day moving average (₩11,713) and above its 60-day moving average (₩12,269). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 58.5, a neutral level. The one-month change is +17.0%, the three-month change is -19.4%, and the position relative to the 52-week high is -59.3%. Relative strength versus the KOSDAQ is 53 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 53% of all stocks. Over the past three months it outpaced the index by 22.4%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M +22.41% / 6M -20.01% / 12M -10.90%
Key metrics Computed vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 2.63x is below the sector median (3.91x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
The operating margin is -300.5%. The debt ratio is 2.0%, so the financial structure is stable.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $2.4M | $1.7M | $2.6M | +59.17% ↑ faster |
| Operating profit | -$12.2M | -$10.8M | -$7.9M | — |
| Net profit | -$6.2M | -$7.2M | -$6.3M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.6M | $21.0M | $2.4M | $1.7M | $2.6M |
| Operating profit | -$6.9M | $1.7M | -$12.2M | -$10.8M | -$7.9M |
| Net profit | -$8.0M | -$4.7M | -$6.2M | -$7.2M | -$6.3M |
| Revenue CAGR | 4-yr avg -7.52% | ||||
Revenue rose 59.2% year over year (2023 ₩3.4 billion → 2024 ₩2.4 billion → 2025 ₩3.8 billion), and the three-year trend is 'mixed'. The pace of growth also quickened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 5 years on record, revenue compound annual growth (CAGR) is -7.5%. The two-year revenue CAGR is 4.9%. In the most recent quarter (Q1 2026), revenue was 20.6% higher than the same period a year earlier.
Latest quarterly results Source Q1 2026 · vs year-ago
Technical indicators Computed
What stands out
- Revenue grew 59.2% year over year, a sign of growth.
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
Recent news & events searched · sourced
- 2026-05-22UpdateReport on the results of a treasury-share disposal - disclosure of the execution details following the May 19 disposal decisionAs a result of the company putting held treasury shares onto the market, it affects near-term circulating volume and cash flow. Source
- 2026-05-19UpdateMaterial-fact report - decision to dispose of treasury sharesDepending on the scale and purpose of the disposal, a medium-term variable from which the direction of fund use can be gauged. Source
- 2026-05-15UpdateQ1 2026 quarterly report - revenue ₩380 million (+20.6%), continuing operating loss confirmedAs confirmed results, a key check document in which revenue growth and a continuing loss are revealed at the same time. Source
- 2026-03-26FilingResults of the general shareholders' meeting and appointment of outside directors - handling of regular governance-related agenda itemsA disclosure for confirming governance such as board composition rather than a direct earnings effect. Source
- 2026-03-18Update2025 business report (consolidated) - annual revenue ₩3.8 billion (+59.2%), operating loss of -₩11.3 billion finalizedAs confirmed annual results, a reference document showing both the revenue recovery and the size of the loss. Source
Figure cross-check computed ↔ external
Recent filings Source
- 2026-05-22OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-22OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-22OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-22OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-22TreasuryTreasury-stock disposal decision
- 2026-05-19TreasuryMaterial-fact report
- 2026-05-15PeriodicQuarterly report
- 2026-03-26Shareholders' meeting notice
- 2026-03-26Disclosure
- 2026-03-18PeriodicAnnual business report
- 2026-03-16Audit report
- 2026-03-11Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.